Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-04-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/917 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689898508877824 |
|---|---|
| author | Yu. Yu. Polyakov E. A. Baryakh E. N. Misyurina E. I. Zhelnova M. A. Mingalimov S. A. Kardovskaya M. Ya. Smolyarchuk T. N. Tolstykh T. S. Chudnova D. D. Ivanova O. L. Kochneva D. V. Lebedev A. U. Abueva A. M. Chistov E. N. Zotina I. V. Samsonova M. A. Lysenko |
| author_facet | Yu. Yu. Polyakov E. A. Baryakh E. N. Misyurina E. I. Zhelnova M. A. Mingalimov S. A. Kardovskaya M. Ya. Smolyarchuk T. N. Tolstykh T. S. Chudnova D. D. Ivanova O. L. Kochneva D. V. Lebedev A. U. Abueva A. M. Chistov E. N. Zotina I. V. Samsonova M. A. Lysenko |
| author_sort | Yu. Yu. Polyakov |
| collection | DOAJ |
| description | Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy. |
| format | Article |
| id | doaj-art-6ad4e363aae34c35b0a8dbd147ff46eb |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2024-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-6ad4e363aae34c35b0a8dbd147ff46eb2025-08-20T03:21:28ZrusABV-pressОнкогематология1818-83462413-40232024-04-0119210110810.17650/1818-8346-2024-19-2-101-108753Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2Yu. Yu. Polyakov0E. A. Baryakh1E. N. Misyurina2E. I. Zhelnova3M. A. Mingalimov4S. A. Kardovskaya5M. Ya. Smolyarchuk6T. N. Tolstykh7T. S. Chudnova8D. D. Ivanova9O. L. Kochneva10D. V. Lebedev11A. U. Abueva12A. M. Chistov13E. N. Zotina14I. V. Samsonova15M. A. Lysenko16City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaCity Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)City Clinical Hospital No. 52, Moscow Healthcare DepartmentMedicine and Nuclear Technologies LLCCity Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)City Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare DepartmentCity Clinical Hospital No. 52, Moscow Healthcare Department; Medical and Biological University of Innovation and Continuing Education, State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological AgencyCity Clinical Hospital No. 52, Moscow Healthcare Department; Peoples’ Friendship University of Russia named after Patrice LumumbaN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaCity Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)City Clinical Hospital No. 52, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaCity Clinical Hospital No. 52, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaTreatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.https://oncohematology.abvpress.ru/ongm/article/view/917new coronavirus infectionprimary central nervous system large b-cell lymphomachemotherapyvirus persistence |
| spellingShingle | Yu. Yu. Polyakov E. A. Baryakh E. N. Misyurina E. I. Zhelnova M. A. Mingalimov S. A. Kardovskaya M. Ya. Smolyarchuk T. N. Tolstykh T. S. Chudnova D. D. Ivanova O. L. Kochneva D. V. Lebedev A. U. Abueva A. M. Chistov E. N. Zotina I. V. Samsonova M. A. Lysenko Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 Онкогематология new coronavirus infection primary central nervous system large b-cell lymphoma chemotherapy virus persistence |
| title | Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 |
| title_full | Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 |
| title_fullStr | Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 |
| title_full_unstemmed | Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 |
| title_short | Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2 |
| title_sort | persistence of a new coronavirus infection in a patient with primary central nervous system large b cell lymphoma with assessment of the humoral immune response against sars cov 2 |
| topic | new coronavirus infection primary central nervous system large b-cell lymphoma chemotherapy virus persistence |
| url | https://oncohematology.abvpress.ru/ongm/article/view/917 |
| work_keys_str_mv | AT yuyupolyakov persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT eabaryakh persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT enmisyurina persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT eizhelnova persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT mamingalimov persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT sakardovskaya persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT myasmolyarchuk persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT tntolstykh persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT tschudnova persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT ddivanova persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT olkochneva persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT dvlebedev persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT auabueva persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT amchistov persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT enzotina persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT ivsamsonova persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 AT malysenko persistenceofanewcoronavirusinfectioninapatientwithprimarycentralnervoussystemlargebcelllymphomawithassessmentofthehumoralimmuneresponseagainstsarscov2 |